Everolimus [EVE1]
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- I confirm that this application is being made by and the first cycle of systemic anti-cancer therapy of everolimus with exemestane will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
- I confirm that the patient has ER +ve, HER2 –ve metastatic breast cancer
- I confirm that the patient has no symptomatic visceral disease
- I confirm that everolimus will be given in combination with exemestane
- I confirm that the patient has had previous treatment with a non-steroidal aromatase inhibitor
- I confirm that the patient has had no previous treatment with exemestane for metastatic breast cancer
- I confirm the patient has received no more than one line of cytotoxic chemotherapy for the treatment of advanced breast cancer.
- I confirm the licensed dose and frequency of everolimus will be used.
NHS funded From: 21 December 2016
Additional information
Current Form Version
Note
The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.
If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.